Cargando…
A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
BACKGROUND: The extend of lung disease remains the most important prognostic factor for survival in patients with cystic fibrosis (CF), and lack of adherence is the main reason for treatment failure. Early detection of deterioration in lung function and optimising adherence are therefore crucial in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058751/ https://www.ncbi.nlm.nih.gov/pubmed/33882893 http://dx.doi.org/10.1186/s12890-021-01500-y |
_version_ | 1783681073486495744 |
---|---|
author | Thee, Stephanie Stahl, Mirjam Fischer, Rainald Sutharsan, Sivagurunathan Ballmann, Manfred Müller, Axel Lorenz, Daniel Urbanski-Rini, Dominika Püschner, Franziska Amelung, Volker Eric Fuchs, Carola Mall, Marcus Alexander |
author_facet | Thee, Stephanie Stahl, Mirjam Fischer, Rainald Sutharsan, Sivagurunathan Ballmann, Manfred Müller, Axel Lorenz, Daniel Urbanski-Rini, Dominika Püschner, Franziska Amelung, Volker Eric Fuchs, Carola Mall, Marcus Alexander |
author_sort | Thee, Stephanie |
collection | PubMed |
description | BACKGROUND: The extend of lung disease remains the most important prognostic factor for survival in patients with cystic fibrosis (CF), and lack of adherence is the main reason for treatment failure. Early detection of deterioration in lung function and optimising adherence are therefore crucial in CF care. We implement a randomized controlled trial to evaluate efficacy of telemonitoring of adherence, lung function, and health condition in combination with behavior change interventions using innovative digital technologies. METHODS: This is a multi-centre, randomized, controlled, non-blinded trial aiming to include 402 patients ≥ 12 years-of-age with CF. A standard-of-care arm is compared to an arm receiving objective, continuous monitoring of adherence to inhalation therapies, weekly home spirometry using electronic devices with data transmission to patients and caring physicians combined with video-conferencing, a self-management app and professional telephone coaching. The duration of the intervention phase is 18 months. The primary endpoint is time to the first protocol-defined pulmonary exacerbation. Secondary outcome measures include number of and time between pulmonary exacerbations, adherence to inhalation therapy, changes in forced expiratory volume in 1 s from baseline, number of hospital admissions, and changes in health-related quality of life. CF-associated medical treatment and care, and health care related costs will be assessed by explorative analysis in both arms. DISCUSSION: This study offers the opportunity to evaluate the effect of adherence interventions using telemedicine capable devices on adherence and lung health, possibly paving the way for implementation of telemedicine in routine care for patients with CF. Trial registration: This study has been registered with the German Clinical Trials Register (Identifier: DRKS00024642, date of registration 01 Mar 2021, URL: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024642). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01500-y. |
format | Online Article Text |
id | pubmed-8058751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80587512021-04-21 A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF Thee, Stephanie Stahl, Mirjam Fischer, Rainald Sutharsan, Sivagurunathan Ballmann, Manfred Müller, Axel Lorenz, Daniel Urbanski-Rini, Dominika Püschner, Franziska Amelung, Volker Eric Fuchs, Carola Mall, Marcus Alexander BMC Pulm Med Study Protocol BACKGROUND: The extend of lung disease remains the most important prognostic factor for survival in patients with cystic fibrosis (CF), and lack of adherence is the main reason for treatment failure. Early detection of deterioration in lung function and optimising adherence are therefore crucial in CF care. We implement a randomized controlled trial to evaluate efficacy of telemonitoring of adherence, lung function, and health condition in combination with behavior change interventions using innovative digital technologies. METHODS: This is a multi-centre, randomized, controlled, non-blinded trial aiming to include 402 patients ≥ 12 years-of-age with CF. A standard-of-care arm is compared to an arm receiving objective, continuous monitoring of adherence to inhalation therapies, weekly home spirometry using electronic devices with data transmission to patients and caring physicians combined with video-conferencing, a self-management app and professional telephone coaching. The duration of the intervention phase is 18 months. The primary endpoint is time to the first protocol-defined pulmonary exacerbation. Secondary outcome measures include number of and time between pulmonary exacerbations, adherence to inhalation therapy, changes in forced expiratory volume in 1 s from baseline, number of hospital admissions, and changes in health-related quality of life. CF-associated medical treatment and care, and health care related costs will be assessed by explorative analysis in both arms. DISCUSSION: This study offers the opportunity to evaluate the effect of adherence interventions using telemedicine capable devices on adherence and lung health, possibly paving the way for implementation of telemedicine in routine care for patients with CF. Trial registration: This study has been registered with the German Clinical Trials Register (Identifier: DRKS00024642, date of registration 01 Mar 2021, URL: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024642). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01500-y. BioMed Central 2021-04-21 /pmc/articles/PMC8058751/ /pubmed/33882893 http://dx.doi.org/10.1186/s12890-021-01500-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Thee, Stephanie Stahl, Mirjam Fischer, Rainald Sutharsan, Sivagurunathan Ballmann, Manfred Müller, Axel Lorenz, Daniel Urbanski-Rini, Dominika Püschner, Franziska Amelung, Volker Eric Fuchs, Carola Mall, Marcus Alexander A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF |
title | A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF |
title_full | A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF |
title_fullStr | A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF |
title_full_unstemmed | A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF |
title_short | A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF |
title_sort | multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: connect cf |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058751/ https://www.ncbi.nlm.nih.gov/pubmed/33882893 http://dx.doi.org/10.1186/s12890-021-01500-y |
work_keys_str_mv | AT theestephanie amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT stahlmirjam amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT fischerrainald amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT sutharsansivagurunathan amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT ballmannmanfred amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT mulleraxel amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT lorenzdaniel amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT urbanskirinidominika amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT puschnerfranziska amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT amelungvolkereric amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT fuchscarola amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT mallmarcusalexander amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT theestephanie multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT stahlmirjam multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT fischerrainald multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT sutharsansivagurunathan multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT ballmannmanfred multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT mulleraxel multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT lorenzdaniel multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT urbanskirinidominika multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT puschnerfranziska multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT amelungvolkereric multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT fuchscarola multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf AT mallmarcusalexander multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf |